An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International

Approval of the vasopressin V2 receptor antagonist tolvaptan—based on the landmark TEMPO 3:4 trial—marked a transformation in the management of autosomal dominant polycystic kidney disease (ADPKD). This development has advanced patient care in ADPKD from general measures to prevent progression of ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Müller, Roman-Ulrich, Messchendorp, A Lianne, Birn, Henrik, Capasso, Giovambattista, Cornec-Le Gall, Emilie, Devuyst, Olivier, van Eerde, Albertien, Guirchoun, Patrick, Harris, Tess, Hoorn, Ewout J, Knoers, Nine V A M, Korst, Uwe, Mekahli, Djalila, Le Meur, Yannick, Nijenhuis, Tom, Ong, Albert C M, Sayer, John A, Schaefer, Franz, Servais, Aude, Tesar, Vladimir, Torra, Roser, Walsh, Stephen B, Gansevoort, Ron T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Special Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035348/
https://www.ncbi.nlm.nih.gov/pubmed/35134221
http://dx.doi.org/10.1093/ndt/gfab312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035348/
https://www.ncbi.nlm.nih.gov/pubmed/35134221
http://dx.doi.org/10.1093/ndt/gfab312

Ejemplares similares